Key Product Details
Lys24-Cys234 & Asn29-Cys234 both with a C-terminal 10-His tag
N-terminal Sequence Analysis
Predicted Molecular Mass
1 μg/mL of rhFGF-BP was mixed with serially diluted rhFGF basic (Catalog # 233-FB). Following incubation, the FGFBP-FGF basic complex was captured on a Gt x hFGFBP-coated plate. Bound FGF basic was measured using biotinylated Gt x hFGF basic. The concentration of rhFGF basic that produces 50% of the optimal binding was found to be approximately 5-20 ng/mL.
Formulation, Preparation and Storage
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Fibroblast growth factor binding protein (FGF-BP), also known as HBp17, is a secreted glycoprotein that increases the bioavailability of FGFs (1). Mature FGF-BP is a 34 kDa, 211 amino acid (aa) O-glycosylated protein with five conserved intrachain disulfide bonds (2 - 4). FGF-BP contains a heparin-binding domain (aa 110 - 143) and a distinct FGF-binding region (aa 193 - 243) (5). Mature human FGF-BP shares 59% and 54% aa sequence identity with mouse and rat FGF-BP, respectively. FGF-BP is expressed throughout development and in adult squamous epithelium (2, 6). It is upregulated in injured skin, renal tubular epithelium, and spinal nerves as well as in carcinomas of the skin, colon, and pancreas (3, 7 - 10). FGF-BP binds FGF-1, -2, -7, -10, and -22 which are secreted and sequestered in the extracellular matrix (ECM) (7, 11). The association of FGF-BP with heparan sulfate proteoglycans (HSPG) weakens HSPG attachment of FGFs and promotes their release (2, 8, 12, 13). FGF-BP enhances the mitogenic effects of FGFs, thereby contributing to epithelial, endothelial, and neuronal tissue repair, angiogenesis, and tumor growth (7 - 9, 11, 14, 15).
- Abuharbeid, S. et al. (2006) Int. J. Biochem. Cell Biol. 38:1463.
- Wu, D. et al. (1991) J. Biol. Chem. 266:16778.
- Tassi, E. et al. (2006) Cancer Res. 66:1191.
- Lametsch, R. et al. (2000) J. Biol. Chem. 275:19469.
- Xie, B. et al. (2006) J. Biol. Chem. 281:1137.
- Aigner, A. et al. (2002) Histochem. Cell Biol. 117:1.
- Beer, H.-D. et al. (2005) Oncogene 24:5269.
- Ray, P.E. et al. (2006) Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R105.
- Tassi, E. et al. (2007) Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R775.
- Kurtz, A. et al. (2004) Neoplasia 6:595.
- Tassi, E. et al. (2001) J. Biol. Chem. 276:40247.
- Mongiat, M. et al. (2001) J. Biol. Chem. 276:10263.
- Kurtz, A. et al. (1997) Oncogene 14:2671.
- Aigner, A. et al. (2001) Int. J. Cancer 92:510.
- Czubayko, F. et al. (1997) Nat. Med. 3:1137.
Product Specific Notices for Recombinant Human FGF-BP Protein, CF
For research use only